X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs NATCO PHARMA - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS NATCO PHARMA IPCA LABS/
NATCO PHARMA
 
P/E (TTM) x 29.7 16.5 180.0% View Chart
P/BV x 3.5 17.8 19.8% View Chart
Dividend Yield % 0.1 0.6 20.7%  

Financials

 IPCA LABS   NATCO PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-18
NATCO PHARMA
Mar-14
IPCA LABS/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs695877 79.3%   
Low Rs400424 94.5%   
Sales per share (Unadj.) Rs260.2223.4 116.5%  
Earnings per share (Unadj.) Rs19.031.1 61.1%  
Cash flow per share (Unadj.) Rs33.140.3 82.1%  
Dividends per share (Unadj.) Rs1.005.00 20.0%  
Dividend yield (eoy) %0.20.8 23.7%  
Book value per share (Unadj.) Rs213.0219.5 97.1%  
Shares outstanding (eoy) m126.2033.07 381.6%   
Bonus/Rights/Conversions -PA-  
Price / Sales ratio x2.12.9 72.3%   
Avg P/E ratio x28.920.9 137.9%  
P/CF ratio (eoy) x16.616.1 102.6%  
Price / Book Value ratio x2.63.0 86.8%  
Dividend payout %5.316.1 32.8%   
Avg Mkt Cap Rs m69,12021,504 321.4%   
No. of employees `00013.3NA-   
Total wages/salary Rs m7,3591,128 652.5%   
Avg. sales/employee Rs Th2,477.4NM-  
Avg. wages/employee Rs Th555.2NM-  
Avg. net profit/employee Rs Th180.6NM-  
INCOME DATA
Net Sales Rs m32,8367,389 444.4%  
Other income Rs m418167 250.1%   
Total revenues Rs m33,2547,556 440.1%   
Gross profit Rs m4,5051,793 251.2%  
Depreciation Rs m1,777304 583.9%   
Interest Rs m240366 65.6%   
Profit before tax Rs m2,9051,290 225.3%   
Minority Interest Rs m046 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m511309 165.6%   
Profit after tax Rs m2,3941,027 233.0%  
Gross profit margin %13.724.3 56.5%  
Effective tax rate %17.623.9 73.5%   
Net profit margin %7.313.9 52.4%  
BALANCE SHEET DATA
Current assets Rs m19,4553,681 528.5%   
Current liabilities Rs m10,0763,123 322.6%   
Net working cap to sales %28.67.6 377.9%  
Current ratio x1.91.2 163.8%  
Inventory Days Days9889 109.4%  
Debtors Days Days6759 114.1%  
Net fixed assets Rs m20,2607,685 263.6%   
Share capital Rs m252331 76.3%   
"Free" reserves Rs m26,6336,670 399.3%   
Net worth Rs m26,8867,259 370.4%   
Long term debt Rs m2,340955 245.1%   
Total assets Rs m41,17311,957 344.3%  
Interest coverage x13.14.5 289.6%   
Debt to equity ratio x0.10.1 66.2%  
Sales to assets ratio x0.80.6 129.1%   
Return on assets %6.411.7 54.9%  
Return on equity %8.914.2 62.9%  
Return on capital %10.820.7 51.9%  
Exports to sales %47.639.4 121.0%   
Imports to sales %14.95.7 260.9%   
Exports (fob) Rs m15,6422,908 537.9%   
Imports (cif) Rs m4,884421 1,159.4%   
Fx inflow Rs m15,6423,445 454.0%   
Fx outflow Rs m4,884703 694.9%   
Net fx Rs m10,7592,743 392.3%   
CASH FLOW
From Operations Rs m3,4111,440 236.8%  
From Investments Rs m-1,354-1,089 124.3%  
From Financial Activity Rs m-1,304-353 369.7%  
Net Cashflow Rs m753-1 -50,550.3%  

Share Holding

Indian Promoters % 45.9 52.0 88.2%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 11.4 7.8 145.4%  
FIIs % 25.3 16.6 152.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 26.0 66.9%  
Shareholders   36,892 25,395 145.3%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   CIPLA  SANOFI INDIA  ALEMBIC PHARMA  SHASUN PHARMA  PFIZER  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Sep 19, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS